Effective, low-cost tools to prevent and treat cervical cancer are available today, with new tools to save even more women just steps from being deployed. Despite this, resources for cervical cancer prevention, screening, and treatment remain insufficient to change the trajectory of this global epidemic.
Better data on current investments in cervical cancer programs in low-income countries (LICs) and lower middle-income countries (LMICs) can inform decision-makers and provide a basis for advocacy for increased financial and political support. This brief highlights investments in HPV immunization and cervical cancer screening and treatment in low-resource settings for 2018 and 2019. Read the new report!
- Total funding for HPV vaccination programs in LICs and LMICs for 2019 is estimated at $65.1 million, an increase of 61.5% from 2018 primarily driven by increased support for HPV vaccination programs by Gavi, the Vaccine Alliance.
- Estimated total funding for cervical cancer screening and treatment in LICs and LMICs totaled $56.2 million USD in 2019, an increase of almost 150% due heavily to the scale-up of the PEPFAR-led Go Further partnership.